Melanoma Patients
Dear Southern Health and Social Care Trust (Northern Ireland),
The following questions are being asked for on behalf of Novartis. The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.
Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
• Bevacizumab (Avastin)
• Dacarbazine (DTIC)
• Trametinib (Mekinist)
• Dabrafenib (Tafinlar)
• Ipilimumab (Yervoy)
• Vemurafenib (Zelboraf)
• Nivolumab (Opdivo)
• Nivolumab + Ipilimumab (Opdivo + Yervoy)
• Pembrolizumab (Keytruda)
• Vemurafenib + cobimetinib (Zelboraf + Cotellic)
• Dabrafenib + Trametinib (Tafinlar + Mekinist)
• Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
• Other active systemic anti-cancer therapy [please state]
• Palliative care only
Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
• Ipilimumab
• Ipilimumab AND Nivolumab
• Nivolumab
• Pembrolizumab
• Dabrafenib AND Trametinib
• Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
• Other active systemic anti-cancer therapy
• Palliative care only
Sincerely thank you for taking the time and resources to answer these questions.
Yours faithfully,
Ben Holdsworth
Thank you for your email.
We acknowledge receipt of your request.
You will be aware of the significant pressures on our health and social
care services during the current surge of the Covid-19 pandemic. During
this time we have been asking our staff to prioritise their professional
caring duties and to support front line health and social care services in
responding to the emergency. This has understandably had an impact on
other duties within their role such as responding to legislative
requirements under FOI and the processing of Subject Access Requests.
We assure you that your request will be logged and processed, and we will
do our utmost to respond as quickly as possible.
Yours faithfully
Information Governance Team
Dear Mr Holdsworth
We acknowledge receipt of your email to Southern Health and Social Care Trust:
Melanoma Patients
If you have submitted a request under the Freedom of Information Act (FOIA) or the Environmental Information Regulations (EIR), your request will be considered and you will receive our response within the statutory timescale of 20 working days.
The reference number for your email is FOI/1202.
Should you have any further inquiries concerning this matter, please reply to this email.
Yours sincerely,
Information Governance Department
Southern Health and Social Care Trust
Dear Mr Holdsworth,
Please see attached response in respect of your recent FOI request to the Southern Health and Social Care Trust.
Kind regards
Gail Fegan
Information Governance Officer
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now